Total Payments
$324,296
2024 Payments
$164.00
Companies
14
Transactions
228
Medicare Patients
1,138
Medicare Billing
$240,516
Payment Breakdown by Category
Other$272,936 (84.2%)
Travel$24,409 (7.5%)
Consulting$22,480 (6.9%)
Food & Beverage$4,212 (1.3%)
Education$258.56 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $272,936 | 95 | 84.2% |
| Travel and Lodging | $24,409 | 39 | 7.5% |
| Consulting Fee | $22,480 | 29 | 6.9% |
| Food and Beverage | $4,212 | 58 | 1.3% |
| Education | $258.56 | 7 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $243,494 | 145 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $61,883 | 63 | $0 (2022) |
| GENZYME CORPORATION | $8,543 | 4 | $0 (2021) |
| GlaxoSmithKline, LLC. | $7,600 | 3 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $1,170 | 1 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $900.00 | 1 | $0 (2018) |
| Celgene Corporation | $300.00 | 1 | $0 (2022) |
| Kite Pharma, Inc. | $120.00 | 1 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $89.99 | 1 | $0 (2021) |
| Epizyme, Inc., | $64.99 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $164.00 | 3 | Kite Pharma, Inc. ($120.00) |
| 2023 | $19,982 | 7 | E.R. Squibb & Sons, L.L.C. ($18,812) |
| 2022 | $25,238 | 18 | E.R. Squibb & Sons, L.L.C. ($24,475) |
| 2021 | $40,472 | 29 | E.R. Squibb & Sons, L.L.C. ($21,116) |
| 2020 | $33,642 | 30 | E.R. Squibb & Sons, L.L.C. ($22,237) |
| 2019 | $26,208 | 19 | E.R. Squibb & Sons, L.L.C. ($18,605) |
| 2018 | $81,479 | 53 | E.R. Squibb & Sons, L.L.C. ($43,132) |
| 2017 | $97,113 | 69 | E.R. Squibb & Sons, L.L.C. ($95,117) |
All Payment Transactions
228 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/03/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $120.00 | General |
| Category: CELLT | ||||||
| 07/01/2024 | Janssen Pharmaceuticals, Inc | RYBREVANT (Drug) | Education | In-kind items and services | $22.00 | General |
| Category: Oncology | ||||||
| 04/22/2024 | Janssen Pharmaceuticals, Inc | RYBREVANT (Drug) | Education | In-kind items and services | $22.00 | General |
| Category: Oncology | ||||||
| 12/12/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,176.00 | General |
| Category: Oncology | ||||||
| 10/06/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,176.00 | General |
| Category: Oncology | ||||||
| 09/14/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $95.37 | General |
| Category: Oncology | ||||||
| 05/24/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,658.00 | General |
| Category: Oncology | ||||||
| 05/09/2023 | Janssen Scientific Affairs, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| Category: Oncology | ||||||
| 03/07/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,623.00 | General |
| Category: Oncology | ||||||
| 02/23/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $83.57 | General |
| Category: Oncology | ||||||
| 12/13/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $450.00 | General |
| Category: Oncology | ||||||
| 12/09/2022 | E.R. Squibb & Sons, L.L.C. | SPRYCEL (Drug) | Education | In-kind items and services | $35.84 | General |
| Category: Oncology | ||||||
| 08/23/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,635.00 | General |
| Category: Oncology | ||||||
| 07/07/2022 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $12.67 | General |
| 06/15/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 06/15/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 06/15/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 06/15/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 05/31/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,625.00 | General |
| Category: Oncology | ||||||
| 05/17/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $1,015.34 | General |
| Category: Oncology | ||||||
| 05/17/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $90.17 | General |
| Category: Oncology | ||||||
| 05/12/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $124.80 | General |
| 05/10/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 05/03/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,625.00 | General |
| Category: Oncology | ||||||
| 05/03/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,625.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 241 | 671 | $178,455 | $56,565 |
| 2022 | 4 | 234 | 704 | $165,751 | $56,573 |
| 2021 | 6 | 301 | 832 | $195,290 | $71,310 |
| 2020 | 6 | 362 | 812 | $173,016 | $56,069 |
Total Patients
1,138
Total Services
3,019
Medicare Billing
$240,516
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 163 | 489 | $114,159 | $36,322 | 31.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 121 | $39,088 | $11,577 | 29.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 29 | 34 | $13,220 | $4,740 | 35.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 27 | 27 | $11,988 | $3,925 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 180 | 606 | $135,792 | $47,712 | 35.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 58 | $18,085 | $4,812 | 26.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 23 | 23 | $9,751 | $3,308 | 33.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 11 | 17 | $2,123 | $739.99 | 34.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 163 | 622 | $133,845 | $50,360 | 37.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 37 | 103 | $30,872 | $8,589 | 27.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 37 | 37 | $15,135 | $5,621 | 37.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 26 | 27 | $9,717 | $4,441 | 45.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 26 | 30 | $3,595 | $1,572 | 43.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 13 | $2,126 | $726.44 | 34.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 169 | 555 | $114,453 | $35,026 | 30.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 30 | 65 | $18,688 | $5,627 | 30.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 33 | 34 | $11,796 | $5,599 | 47.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 33 | 33 | $12,932 | $4,638 | 35.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 80 | 107 | $12,283 | $4,408 | 35.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 17 | 18 | $2,864 | $771.14 | 26.9% |
About Dr. Ritesh Rathore, MD
Dr. Ritesh Rathore, MD is a Hematology & Oncology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1467459263.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ritesh Rathore, MD has received a total of $324,296 in payments from pharmaceutical and medical device companies, with $164.00 received in 2024. These payments were reported across 228 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($272,936).
As a Medicare-enrolled provider, Rathore has provided services to 1,138 Medicare beneficiaries, totaling 3,019 services with total Medicare billing of $240,516. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Providence, RI
- Active Since 07/07/2005
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1467459263
Products in Payments
- OPDIVO (Biological) $214,355
- IMFINZI (Drug) $33,943
- EMPLICITI (Biological) $24,168
- TAGRISSO (Drug) $20,580
- BLENREP (Biological) $7,600
- SARCLISA (Biological) $7,191
- IMFINZI (Biological) $5,305
- RYBREVANT (Drug) $1,214
- Stivarga (Drug) $900.00
- Yescarta (Drug) $120.00
- JEVTANA (Drug) $89.99
- TAZVERIK (Drug) $64.99
- Avastin (Biological) $36.93
- SPRYCEL (Drug) $35.84
- XOSPATA (Drug) $24.88
- Nerlynx (Drug) $12.62
- Pomalyst (Drug) $11.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Providence
Anthony Mega, Md, MD
Hematology & Oncology — Payments: $193,307
Hematology & Oncology $193,307
Dr. Adam Olszewski, M.d, M.D
Hematology & Oncology — Payments: $47,507
Hematology & Oncology $47,507
John Reagan, Md, MD
Hematology & Oncology — Payments: $35,520
Hematology & Oncology $35,520
Hina Khan, M.d, M.D
Hematology & Oncology — Payments: $19,225
Hematology & Oncology $19,225
Dr. Joseph Dibenedetto, Md, MD
Hematology & Oncology — Payments: $6,205
Hematology & Oncology $6,205
Robert Sokolic, M.d, M.D
Hematology & Oncology — Payments: $5,699
Hematology & Oncology $5,699